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No related serious adverse events were observed. The
eactogenicity proﬁle was comparable to that of the con-
rol vaccines. No increase in reactogenicity was observed:
n children compared with adults, or after the second or
hird dose compared with the ﬁrst. In both non-endemic and
ndemic populations, immune responses increased incre-
entally after each of the 3 doses of TDV and were balanced
gainst the 4 serotypes after 3 doses.
TDV was well tolerated and immunogenic in children in
oth endemic and non-endemic areas with a 3 dose sched-
le.
oi:10.1016/j.ijid.2010.02.1858
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The Global Pertussis Initiative (GPI) was established in
001 to evaluate the ongoing problem of pertussis worldwide
nd to recommend appropriate pertussis control strategies.
n addition to primary vaccinations, the GPI currently recom-
ends pertussis booster vaccination to pre-school children,
dolescents, and those adults at risk of transmitting Bor-
etella pertussis infection to infants. The GPI actively
ncourages efforts toward global standardization of pertus-
is disease clinical deﬁnitions and diagnostics. At a meeting
n Paris in January 2010, GPI members discussed pertussis
urveillance and testing, and prepared recommendations on
he implementation and utilization of these activities. Issues
nd projects discussed included:
Advantages and limitations of various national surveil-
lance systems;
Seroprevalence studies;
Ideal surveillance methodologies;
Ongoing efforts in standardization of real time PCR, cul-
ture, serology and sample treatment;
Likely future advances (eg, antibody detection in saliva).
Previous regional meetings of the GPI have conﬁrmed
hat many countries have limited laboratory facilities for
he detection of pertussis. The GPI hopes that the future
ntroduction of increased laboratory capabilities and greater
armonization of clinical deﬁnitions and detection methods
ill lead to enhanced surveillance and a better estimate of
he burden of pertussis infection worldwide.
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Pertussis disease in infancy remains a signiﬁcant prob-
em, with a high risk of serious morbidity and mortality
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n both developed and developing countries. Improved dis-
ase prevention strategies are imperative. In countries with
stablished childhood vaccination programs, studies have
hown that adults are the predominant source of infec-
ion for infants. Therefore strategies to protect infants now
mphasise vaccination of adults, particularly those (eg, par-
nts, close household contacts and health-care workers) at
igh risk of transmitting infection to infants. A cocoon strat-
gy, in which all potential adolescent and adult contacts of
nfants are vaccinated, is probably the most cost-effective
olution.
Postpartum vaccination program of new mothers are
ngoing in the US. The introduction of booster doses in
dolescents has been an important step toward decreas-
ng disease burden. For example, in areas of Canada where
dap vaccine has been administered to 14- to 16-year-
lds, marked reductions of pertussis have been observed in
dolescents and younger age groups, possibly due to herd
mmunity.
Adult disease in itself is a concern, with the true adult
urden estimated at more than 600,000 cases annually in
he United States. Adults commonly have a persistent cough
or up to 4 months, often requiring medical treatment for
he associated morbidity and to reduce the risk of infec-
ion to others. Furthermore, it can have signiﬁcant ﬁnancial
mplications for the patient and society. Evidence suggests
hat implementation of adult vaccination programs could be
ighly cost-effective and even cost-saving. This presentation
ill review available data on pertussis vaccination of adults
nd adolescents, and assesses the potential impact of such
accination, both now and in the future.
oi:10.1016/j.ijid.2010.02.1860
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Tick-borne encephalitis virus (TBEV), a member of the
amily Flaviviridae, causes substantial morbidity and even
ortality in endemic areas. The distribution of TBEV cov-
rs many countries in Europe and large parts of central
nd eastern Asia. Although most infections with TBEV are
symptomatic, more than 10,000 severe cases are reported
nnually, and the incidence has increased considerably dur-
ng the last few decades. Up to 46% of patients are left
